Monday, August 25th, 2025
Stock Profile: DRMA
DRMA Logo

Dermata Therapeutics, Inc. (DRMA)

Market: NASD | Currency: USD

Address: 3525 Del Mar Heights Road

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in Show more




📈 Dermata Therapeutics, Inc. Historical Chart






📊 Statistics





💰 Dividend History


Year Annual Yield (%) Total Amount Current Yield (%) Ex Date Pay Date Particulars
2024 - $0.066667 - 2024-05-16 - Stock split
Total Amount for 2024: $0.066667
2023 - $0.062500 - 2023-03-14 - Stock split
Total Amount for 2023: $0.062500


📅 Earnings & EPS History for Dermata Therapeutics, Inc.


DateReported EPS
2025-08-13-1.66
2025-05-14-4.5
2025-03-17-13.4
2024-11-13-20.4
2024-08-07-41.8
2024-05-15-4.7
2024-03-21-31.5
2023-11-09-81
2023-08-10-94.5
2023-05-11-340.5
2023-02-21-288
2022-11-10-480
2022-08-15-576
2022-05-16-792
2022-03-28-1944
2021-11-15-2064
2021-09-27-1680




📰 Related News & Research


No related articles found for "dermata therapeutics".